Literature DB >> 11685800

Hepatitis C virus. The importance of viral heterogeneity.

P Farci1.   

Abstract

Although recent evidence indicates that the quasispecies nature of HCV constitutes a critical strategy for the virus to survive in the host, the mechanisms of viral persistence remain unknown. Similarly, the correlates of immune protection in a limited proportion of individuals who succeed in clearing HCV are still largely undefined. Understanding the mechanisms of sterilizing immunity is essential for devising preventive measures against HCV and unraveling how the virus eludes such immunity. As in other viral infections, the complex interactions between the virus and the host early in the course of HCV infection probably determine the outcome of the disease (i.e., resolution or persistence). The evidence now accumulated on HCV and other models of viral infection is compatible with the hypothesis that both cellular and humoral components are needed for definitive viral clearance. Nevertheless, detailed studies of the specific cellular and humoral immune responses during the incubation period and the acute phase of hepatitis C, in relation to the viral quasispecies evolution and the clinical outcome, are still lacking both in humans and in the chimpanzee model. Until such studies are performed, most ideas of viral clearance mechanisms remain hypothetical, and the immunologic basis of HCV clearance will continue to be inferred from associations rather than from causal relationships.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685800     DOI: 10.1016/s1089-3261(05)70200-2

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  7 in total

1.  Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity.

Authors:  Pavel Skums; Leonid Bunimovich; Yury Khudyakov
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

Review 2.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

3.  Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.

Authors:  James Lara; Guoliang Xia; Mike Purdy; Yury Khudyakov
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

4.  The association of human immunodeficiency virus infection with spontaneously resolved hepatitis C virus infection and level of viremia among injection drug users.

Authors:  Karen H Seal; Alex Monto; Lorna Dove; Hui Shen; Eric Vittinghoff; Daniel Tracy; Erica Miller; Eva Lau; Teresa L Wright
Journal:  Dig Dis Sci       Date:  2007-04-19       Impact factor: 3.199

Review 5.  Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections.

Authors:  Magdalena Figlerowicz; Magdalena Alejska; Anna Kurzyńska-Kokorniak; Marek Figlerowicz
Journal:  Med Res Rev       Date:  2003-07       Impact factor: 12.944

6.  SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes.

Authors:  Brenda Martínez-González; María Eugenia Soria; Lucía Vázquez-Sirvent; Cristina Ferrer-Orta; Rebeca Lobo-Vega; Pablo Mínguez; Lorena de la Fuente; Carlos Llorens; Beatriz Soriano; Ricardo Ramos; Marta Cortón; Rosario López-Rodríguez; Carlos García-Crespo; Isabel Gallego; Ana Isabel de Ávila; Jordi Gómez; Luis Enjuanes; Llanos Salar-Vidal; Jaime Esteban; Ricardo Fernandez-Roblas; Ignacio Gadea; Carmen Ayuso; Javier Ruíz-Hornillos; Nuria Verdaguer; Esteban Domingo; Celia Perales
Journal:  Microbiol Spectr       Date:  2022-03-29

7.  Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.

Authors:  Steven W Ludmerer; Donald J Graham; Evelyn Boots; Edward M Murray; Amy Simcoe; Eric J Markel; Jay A Grobler; Osvaldo A Flores; David B Olsen; Daria J Hazuda; Robert L LaFemina
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.